Vesicare
formulated for overactive bladder syndrome to mitigate urgency symptoms.
Strengths: 5 · 10mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Antimuscarinic
- Pharmacological class
Antimuscarinic
- Precautions and warnings
caution in patients with glaucoma; may impair ability to drive
- Minor side effects
dry mouth; constipation
- Moderate side effects
dyspepsia; blurred vision
- Serious side effects
intestinal obstruction — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
formulated for overactive bladder syndrome to mitigate urgency symptoms.
- Prescription status
POM
- Manufacturer
Astellas Pharma
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
ketoconazole; verapamil
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Use with caution during pregnancy.
Contraindications
hypersensitivity to solifenacin; urinary retention; severe gastrointestinal conditions
Mechanism of action
Competitive muscarinic receptor antagonist that inhibits bladder contraction by blocking cholinergic pathways, which helps manage incontinence and increased bladder sensitivity effectively.
Vesicare
formulated for overactive bladder syndrome to mitigate urgency symptoms.
Editorial Notes
- Active ingredient(s): Solifenacin
- Listed indication(s): Overactive Bladder
Usually available as
- 60 tablets - 5 mg1114-5-mg-15006
- 60 tablets - 10 mg1114-10-mg-15011